Eli Lilly: potential new indication for Jardiance
(CercleFinance.com) - Eli Lilly has announced that the US FDA has agreed to review its supplemental new drug application (sNDA) for Jardiance (empagliflozin) for a potential new indication to lower blood glucose levels in children aged 10 years and older who suffer from type 2 diabetes.
"There are clear unmet needs for young people living with type 2 diabetes, which has nearly doubled in prevalence in people aged 10-19 over the past two decades," said Mohamed Eid, vice president, Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc., an Eli Lilly partner.
"We look forward to working closely with the FDA during the review process and while we await a decision on our efforts to bring another potential treatment option to children 10 years and older with type 2 diabetes," he added.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
"There are clear unmet needs for young people living with type 2 diabetes, which has nearly doubled in prevalence in people aged 10-19 over the past two decades," said Mohamed Eid, vice president, Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc., an Eli Lilly partner.
"We look forward to working closely with the FDA during the review process and while we await a decision on our efforts to bring another potential treatment option to children 10 years and older with type 2 diabetes," he added.
Copyright (c) 2023 CercleFinance.com. All rights reserved.